Heyuan Biotechnology (Tianjin) Co.

, Ltd., Ltd. specializes in cell and gene therapy solutions., Ltd. primarily focuses on the development and manufacture of innovative cell and gene therapies.® (Inaticabtagene Autoleucel Injection, CNCT19), offers a breakthrough treatment for hematological malignancies, specifically targeting CD19 in leukemia patients. The therapy utilizes CAR-T cell technology to engineer patients' T cells to better combat cancer cells., Ltd.®. Sales occur via partnerships with healthcare institutions, allowing medical facilities to directly access the therapy for patients. This model ensures streamlined treatment pathways and includes collaborations with leading medical institutions, which may involve training programs for clinical application., Ltd. The company plans to focus on international markets beginning in the next few years, targeting regions where advanced cancer therapies are in demand.

1. Series C

   Jul 12, 2021

   Amount

   $62M

   Investors

   Locked

2. Series C

   Nov 19, 2020

   Amount

   $69M

   Investors

   Locked

3. Series A

   Jul 9, 2019

   Amount

   $15M

   Investors

   Locked

4. Series A

   Dec 12, 2018

   Amount

   $24M

   Investors

   Locked